Contribution by Nicholas Sammut
HITRIplus is pleased to announce a one-week online international specialised course on Clinical Aspects of Heavy Ion Cancer Therapy Research which will be held from the 3rd to the 7th of July 2023, online on Zoom. For more information, please click here.
It is free of charge and is funded by the European Union’s H2020 research and innovation programme through the HITRIplus project.
This school will cover clinical aspects and it is primarily intended for medical students specialising, or who are considering to specialise, in oncology as well as clinicians of all levels in radiotherapy and particle therapy. The course will be delivered by over 35 world-leading clinicians in the field and will focus on head and neck, sarcoma, prostate, liver, pancreas, gynae and rare indications, re-irradiation, innovative methods, organ motion, treatment planning, present and future clinical trials and radiobiology.
The course also includes a “train-the-trainer” session inspired by the very popular ‘May 2021 HITRIplus Masterclass school’. This is based on the professional, open-source, research toolkit ‘matRad’, tailored to students’ and researchers’ requirements in treatment planning.
In order to enhance active interaction and participation between students and lecturers as well as networking amongst the students, the school includes online networking student events organised in the evenings.
The lectures will also be recorded so they will be immediately available for participants in different time zones.
The school organisers would like to take the opportunity to acknowledge the contributions of leading research institutions and hadron therapy facilities, that are collaborating to deliver this course. Among these are the: South-East European International Institute for Sustainable Technologies (SEEIIST), European Organisation for Nuclear Research (CERN), Heidelberger Ionenstrahl-Therapiezentrum (HIT), National Institutes for Quantum Science and Technology (QST), Centro Nazionale di Adroterapia Oncologica (CNAO), EBG GmbH MedAustron, Helmholtzzentrum fur Schwerionenforschung (GSI), Marburger Ionenstrahl-Therapiezentrum (MIT), Advanced Resource Center for HADrontherapy (ARCHADE), Deutsches Krebsforschungszentrum (DKFZ), Istituto Europeo di Oncologia (IEO), Mayo Clinic, ExtreMe Matter Institute (EMMI), European Network for Light Ion Hadron Therapy (ENLIGHT), Facility for Antiproton and Ion Research in Europe (FAIR), Gunma University Heavy Ion Medical Center, Aristotle University of Thessaloniki(AUTh), the University of Texas Southwestern Medical Centre, the University of California San Francisco and the University of Malta.
